Genetic variation, β-blockers, and perioperative myocardial infarction

Anesthesiology

Volumn 115, Issue 6, 2011, Pages 1316-1327

  Nagele, Peter ^a   Liggett, Stephen B ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450; G PROTEIN COUPLED RECEPTOR KINASE 5; METOPROLOL;

ACUTE CORONARY SYNDROME; ALLELE; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CORONARY ARTERY THROMBOSIS; DNA STRAND; DRUG EFFICACY; DRUG SAFETY; EPIDEMIC; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PERIOPERATIVE COMPLICATION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; CYTOCHROME P-450 CYP2D6; GENETIC VARIATION; HUMANS; MYOCARDIAL INFARCTION; PERIOPERATIVE PERIOD; POLYMORPHISM, GENETIC; POSTOPERATIVE COMPLICATIONS; RISK FACTORS;

EID: 81855169604     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e3182315eb2     Document Type: Article

References (105)

1. Fleischmann KE, Beckman JA, Buller CE, Calkins H, Fleisher LA, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Robb JF, Valentine RJ: 2009 ACCF/AHA Focused Update on Perioperative Beta Blockade. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 2009; 120:e169-276
2. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischmann KE, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF: ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines Circulation 2007; 116:e418-99
3. POISE Study Group, Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, Xavier D, Chrolavicius S, Greenspan L, Pogue J, Pais P, Liu L, Xu S, Málaga G, Avezum A, Chan M, Montori VM, Jacka M, Choi P: Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): A randomised controlled trial. Lancet 2008; 371:1839-47
4. Poldermans D, Devereaux PJ: The experts debate: Perioperative beta-blockade for noncardiac surgery-proven safe or not? Cleve Clin J Med 2009; 76:S84-92
5. Dorn GW, Liggett SB: Mechanisms of pharmacogenomic effects of genetic variation within the cardiac adrenergic network in heart failure. Mol Pharmacol 2009; 76:466-80
6. Liggett SB: Polymorphisms of adrenergic receptors: Variations on a theme. Assay Drug Dev Technol 2003; 1:317-26
7. Shin J, Johnson JA: Pharmacogenetics of β-blockers. Pharmacotherapy 2007; 27:874-87
8. Small KM, McGraw DW, Liggett SB: Pharmacology and Physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 2003; 43:381-411
9. Bijl MJ, Visser LE, van Schaik RHN, Kors JA, Witteman JCM, Hofman A, Vulto AG, van Gelder T, Stricker B: Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in β blocker users. Clin Pharmacol Ther 2008; 85:45-50
10. Goryachkina K, Burbello A, Boldueva S, Babak S, Bergman U, Bertilsson L: CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction. Eur J Clin Pharmacol 2008; 64:1163-73
11. Rau T, Wuttke H, Michels LM, Werner U, Bergmann K, Kreft M, Fromm MF, Eschenhagen T: Impact of the CYP2D6 genotype on the clinical effects of metoprolol: A prospective longitudinal study. Clin Pharmacol Ther 2008; 85: 269-72
12. Wuttke H, Rau T, Heide R, Bergmann K, Bohm M, Weil J, Werner D, Eschenhagen T: Increased frequency of cytochrome P450 2D6 metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 2002; 72:429-37
13. Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF: Oxidation phenotype-a major determinant of metoprolol metabolism and response. N Engl J Med 1982; 307:1558-60
14. POBBLE Trial Investigators: Perioperative β-blockade (Pobble) for patients undergoing infrarenal vascular surgery: Results of a randomized double-blind controlled trial. J Vasc Surg 2005; 41:602-9
15. Juul AB, Wetterslev J, Gluud C, Kofoed-Enevoldsen A, Jensen G, Callesen T, Norgaard P, Fruergaard K, Bestle M, Vedelsdal R, Miran A, Jacobsen J, Roed J, Mortensen M-B, Jorgensen L, Jorgensen J, Rovsing M-L, Petersen PL, Pott F, Haas M, Albret R, Nielsen LL, Johansson G, Stjernholm P, Molgaard Y, Foss NB, Elkjaer J, Dehlie B, Boysen K, Zaric D, Munksgaard A, Madsen JB, Oberg B, Khanykin B, Blemmer T, Yndgaard S, Perko G, Wang LP, Winkel P, Hilden J, Jensen P, Salas N, DIPOM Trial Group: Effect of perioperative - blockade in patients with diabetes undergoing major non-cardiac surgery: Randomised placebo controlled, blinded multicentre trial. BMJ 2006; 332:1482
16. Wallace A, Layug B, Tateo I, Li J, Hollenberg M, Browner W, Miller D, Mangano DT: Prophylactic atenolol reduces postoperative myocardial ischemia. ANESTHESIOLOGY 1998; 88: 7-17
17. Yang H, Raymer K, Butler r, Parlow J, Roberts R: The effects of perioperative β-blockade: Results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial. Am Heart J 2006; 152:983-90
18. Zaugg M, Bestmann L, Wacker J, Lucchinetti E, Boltres A, Schulz C, Hersberger M, Kälin G, Furrer L, Hofer C, Blumenthal S, Müller A, Zollinger A, Spahn DR, Borgeat A: Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block: The Swiss Beta Blocker in Spinal Anesthesia (BBSA) Study: A double-blinded, placebo-controlled, multicenter trial with 1-year follow-up. ANESTHESIOLOGY 2007; 107:33-44
19. Devereaux PJ, Goldman L, Cook DJ, Gilbert K, Leslie K, Guyatt GH: Perioperative cardiac events in patients undergoing noncardiac surgery: A review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. Can Med Assoc J 2005; 173:627-34
20. Landesberg G, Beattie WS, Mosseri M, Jaffe AS, Alpert JS: Perioperative myocardial infarction. Circulation 2009; 119: 2936-44
21. Ghaferi AA, Birkmeyer JD, Dimick JB: Variation in hospital mortality associated with inpatient surgery. N Engl J Med 2009; 361:1368-75
22. Badner NH, Knill RL, Brown JE, Novick TV, Gelb AW: Myocardial infarction after noncardiac surgery. ANESTHESIOLOGY 1998; 88:572-8
23. Landesberg G, Mosseri M, Zahger D, Wolf Y, Perouansky M, Anner H, Drenger B, Hasin Y, Berlatzky Y, Weissman C: Myocardial infarction after vascular surgery: The role of prolonged stress-induced, ST depression-type ischemia. J Am Coll Cardiol 2001; 37:1839-45
24. Le Manach Y, Perel A, Coriat P, Godet G, Bertrand M, Riou B: Early and delayed myocardial infarction after abdominal aortic surgery. ANESTHESIOLOGY 2005; 102:885-91
25. Landesberg G, Vesselov Y, Einav S, Goodman S, Sprung CL, Weissman C: Myocardial ischemia, cardiac troponin, and long-term survival of high-cardiac risk critically ill intensive care unit patients. Crit Care Med 2005; 33:1281-7
26. Ouyang P, Gerstenblith G, Furman WR, Golueke PJ, Gottlieb SO: Frequency and significance of early postoperative silent myocardial ischemia in patients having peripheral vascular surgery. Am J Cardiol 1989; 64:1113-6
27. Raby KE, Barry J, Creager MA, Cook EF, Weisberg MC, Goldman L: Detection and significance of intraoperative and postoperative myocardial ischemia in peripheral vascular surgery. JAMA 1992; 268:222-7
28. Thygesen K, Alpert JS, White HD, on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction: Universal Definition of Myocardial Infarction. Circulation 2007;116: 2634-53
29. White HD, Chew DP: Acute myocardial infarction. Lancet 2008; 372:570-84
30. Libby P, Theroux P: Pathophysiology of coronary artery disease. Circulation 2005; 111:3481-8
31. Libby P: Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104:365-72
32. Le Manach Y, Coriat P, Collard CD, Riedel B: Statin therapy within the perioperative period. ANESTHESIOLOGY 2008; 108: 1141-6
33. Ouattara A, Benhaoua H, Le Manach Y, Mabrouk-Zerguini N, Itani O, Osman A, Landi M, Riou B, Coriat P: Perioperative statin therapy is associated with a significant and dosedependent reduction of adverse cardiovascular outcomes after coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2009; 23:633-8
34. Adams JE, Sicard GA, Allen BT, Bridwell KH, Lenke LG, Davila-Roman VG, Bodor GS, Ladenson JH, Jaffe AS: Diagnosis of perioperative myocardial infarction with measurement of cardiac troponin I. N Engl J Med 1994; 330:670-4
35. Bursi F, Babuin L, Barbieri A, Politi L, Zennaro M, Grimaldi T, Rumolo A, Gargiulo M, Stella A, Modena MG, Jaffe AS: Vascular surgery patients: Perioperative and long-term risk according to the ACC/AHA guidelines, the additive role of post-operative troponin elevation. Eur Heart J 2005; 26: 2448-56
36. Kim LJ, Martinez EA, Faraday N, Dorman T, Fleisher LA, Perler BA, Williams GM, Chan D, Pronovost PJ: Cardiac troponin I predicts short-term mortality in vascular surgery patients. Circulation 2002; 106:2366-71
37. Landesberg G, Mosseri M, Shatz V, Akopnik I, Bocher M, Mayer M, Anner H, Berlatzky Y, Weissman C: Cardiac troponin after major vascular surgery: The role of perioperative ischemia, preoperative thallium scanning, and coronary revascularization. J Am Coll Cardiol 2004; 44:569-75
38. Landesberg G, Mosseri M, Wolf Y, Vesselov Y, Weissman C: Perioperative myocardial ischemia and infarction: Identification by continuous 12-lead electrocardiogram with online ST-segment monitoring. ANESTHESIOLOGY 2002; 96:264-70
39. Landesberg G, Shatz V, Akopnik I, Wolf YG, Mayer M, Berlatzky Y, Weissman C, Mosseri M: Association of cardiac troponin, CK-MB, and postoperative myocardial ischemia with long-term survival after major vascular surgery. J Am Coll Cardiol 2003; 42:1547-54
40. Lopez-Jimenez F, Goldman L, Sacks DB, Thomas EJ, Johnson PA, Cook EF, Lee TH: Prognostic value of cardiac troponin T after noncardiac surgery: 6-month follow-up data. J Am Coll Cardiol 1997; 29:1241-5
41. Martinez EA, Nass CM, Jermyn RM, Rosenbaum SH, Akhtar S, Chan DW, Malkus H, Weiss JL, Fleisher LA: Intermittent cardiac troponin-I screening is an effective means of surveillance for a perioperative myocardial infarction. J Cardiothorac Vasc Anesth 2005; 19:577-82
42. ISIS-1: Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 1986;2: 57-66
43. The MIAMI Trial Research Group: Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group. Eur Heart J 1985; 6:199-226
44. Mangano DT, Layug EL, Wallace A, Tateo I: Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 1996; 335:1713-20
45. Wallace A, Layug B, Tateo I, Li J, Hollenberg M, Browner W, Miller D, Mangano DT: Prophylactic atenolol reduces postoperative myocardial ischemia. McSPI Research Group. ANESTHESIOLOGY 1998; 88:7-17
46. Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LLM, Blankensteijn JD, Baars HF, Yo T-I, Trocino G, Vigna C, Roelandt JRTC, van Urk H, Fioretti PM, Paelinck B, The Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study G: The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N Engl J Med 1999; 341:1789-94
47. Eagle KA, Berger PB, Calkins H, Chaitman BR, Ewy GA, Fleischmann KE, Fleisher LA, Froehlich JB, Gusberg RJ, Leppo JA, Ryan T, Schlant RC, Winters WL, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Jacobs AK, Hiratzka LF, Russell RO, Smith SC: ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). J Am Coll Cardiol 2002; 39:542-53
48. Devereaux PJ, Beattie WS, Choi PTL, Badner NH, Guyatt GH, Villar JC, Cina CS, Leslie K, Jacka MJ, Montori VM, Bhandari M, Avezum A, Cavalcanti AB, Giles JW, Schricker T, Yang H, Jakobsen C-J, Yusuf S: How strong is the evidence for the use of perioperative β blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials BMJ 2005; 331:313-21
49. Bangalore S, Wetterslev J, Pranesh S, Sawhney S, Gluud C, Messerli FH: Perioperative β blockers in patients having non-cardiac surgery: A meta-analysis. Lancet 2008; 372: 1962-76
50. Ellenberger C, Tait G, Beattie WS: Chronic β blockade is associated with a better outcome after elective noncardiac surgery than acute β blockade: A single-center propensitymatched cohort study. ANESTHESIOLOGY 2011; 114:817-23
51. Wallace AW, Au S, Cason BA: Association of the pattern of use of perioperative β-blockade and postoperative mortality. ANESTHESIOLOGY 2010; 113:794-805
52. Hein L, Altman JD, Kobilka BK: Two functionally distinct α2-adrenergic receptors regulate sympathetic neurotransmission. Nature 1999; 402:181-4
53. Schelb V, Gobel I, Khairallah L, Zhou H, Cox SL, Trendelenburg AU, Hein L, Starke K: Postnatal development of presynaptic receptors that modulate noradrenaline release in mice. Naunyn Schmiedebergs Arch Pharmacol 2001; 364: 359-71
54. Bristow MR, Murphy GA, Krause-Steinrauf H, Anderson JL, Carlquist JF, Thaneemit-Chen S, Krishnan V, Abraham WT, Lowes BD, Port JD, Davis GW, Lazzeroni LC, Robertson AD, Lavori PW, Liggett SB: An a2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the-blocker bucindolol in chronic heart failure. Circ Heart Fail 2010; 3:21-8
55. Small KM, Liggett SB: Identification and functional characterization of α2-adrenoceptor polymorphisms. Trends Pharmacol Sci 2001; 22:471-7
56. Small KM, Forbes SL, Brown KM, Liggett SB: An asn to lys polymorphism in the third intracellular loop of the human alpha 2A-adrenergic receptor imparts enhanced agonistpromoted Gi coupling. J Biol Chem 2000; 275:38518-23
57. Small KM, Forbes SL, Rahman FF, Bridges KM, Liggett SB: A four Amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem 2000; 275:23059-64
58. Gerson MC, Wagoner LE, McGuire N, Liggett SB: Activity of the uptake-1 norepinephrine transporter as measured by I-123 MIBG in heart failure patients with a loss-of-function polymorphism of the presynaptic alpha2C-adrenergic receptor. J Nucl Cardiol 2003; 10:583-9
59. Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB: Synergistic polymorphisms of beta1-and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002; 347:1135-42
60. Zhu WZ, Zheng M, Koch WJ, Lefkowitz RJ, Kobilka BK, Xiao RP: Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci U S A 2001; 98:1607-12
61. Mason DA, Moore JD, Green SA, Liggett SB: A gain-offunction polymorphism in a G-protein coupling domain of the human 1-adrenergic receptor. J Biol Chem 1999; 274: 12670-4
62. Mialet Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A, Dorn GW, Liggett SB: Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 2003; 9:1300-5
63. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, Nelson B, Morrison J, Domanski MJ, Wagoner LE, Abraham WT, Anderson JL, Carlquist JF, Krause-Steinrauf HJ, Lazzeroni LC, Port JD, Lavori PW, Bris-tow MR: A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and betablocker response in human heart failure. Proc Natl Acad Sci U S A 2006; 103:11288-93
64. Rathz DA, Gregory KN, Fang Y, Brown KM, Liggett SB: Hierarchy of polymorphic variation and desensitization permutations relative to 1-and 2-adrenergic receptor signaling. J Biol Chem 2003; 278:10784-9
65. Wagoner LE, Craft LL, Zengel P, McGuire N, Rathz DA, Dorn GW 2nd, Liggett SB: Polymorphisms of the β1-adrenergic receptor predict exercise capacity in heart failure. Am Heart J 2002; 144:840-6
66. Sehnert AJ, Daniels SE, Elashoff M, Wingrove JA, Burrow CR, Horne B, Muhlestein JB, Donahue M, Liggett SB, Anderson JL, Kraus WE: Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol 2008; 52:644-51
67. Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF: Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 2003; 74:44-52
68. Pacanowski MA, Gong Y, Cooper-DeHoff RM, Schork NJ, Shriver MD, Langaee TY, Pepine CJ, Johnson JA: β-adrenergic receptor gene polymorphisms and β-blocker treatment outcomes in hypertension. Clin Pharmacol Ther 2008; 84: 715-21
69. Rathz DA, Brown KM, Kramer LA, Liggett SB: Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol 2002; 39:155-60
70. Green SA, Cole G, Jacinto M, Innis M, Liggett SB: A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 1993; 268:23116-21
71. Turki J, Lorenz JN, Green SA, Donnelly ET, Jacinto M, Liggett SB: Myocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice. Proc Natl Acad Sci U S A 1996; 93:10483-8
72. Wagoner LE, Craft LL, Singh B, Suresh DP, Zengel PW, McGuire N, Abraham WT, Chenier TC, Dorn GW 2nd, Liggett SB: Polymorphisms of the beta(2)-adrenergic receptor determine exercise capacity in patients with heart failure. Circ Res 2000; 86:834-40
73. Liggett SB, Wagoner LE, Craft LL, Hornung RW, Hoit BD, McIntosh TC, Walsh RA: The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 1998; 102:1534-9
74. Green SA, Turki J, Bejarano P, Hall IP, Liggett SB: Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 1995; 13:25-33
75. Green SA, Turki J, Innis M, Liggett SB: Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994; 33:9414-9
76. Liggett SB, Hall IP: β2-adrenergic receptor polymorphisms and asthmatic phenotypes, Genetics of Asthma and COPD. Edited by Postma DS, Weiss ST. New York, Taylor & Francis, 2006, pp 299-316
77. de Groote P, Lamblin N, Helbecque N, Mouquet F, Mc Fadden E, Hermant X, Amouyel P, Dallongeville J, Bauters C: The impact of beta-adrenoreceptor gene polymorphisms on survival in patients with congestive heart failure. Eur J Heart Fail 2005; 7:966-73
78. Kaye DM, Smirk B, Williams C, Jennings G, Esler M, Holst D: β-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics 2003; 13:379-82
79. Raake PW, Koch WJ, Most P: Polymorphisms present in G-protein-coupled receptor kinases and their effect on β-blocker treatment. Pharmacogenomics 2011; 12:295-7
80. Redfern G, Rodseth RN, Biccard BM: Outcomes in vascular surgical patients with isolated postoperative troponin leak: A meta-analysis. Anaesthesia 2011; 66:604-10
81. Dessy C, Balligand JL: Beta3-adrenergic receptors in cardiac and vascular tissues emerging concepts and therapeutic perspectives. Adv Pharmacol 2010; 59:135-63
82. Birenbaum A, Tesse A, Loyer X, Michelet P, Andriantsitohaina R, Heymes C, Riou B, Amour J: Involvement of β3-adrenoceptor in altered β-adrenergic response in senescent heart: Role of nitric oxide synthase 1-derived nitric oxide. ANESTHESIOLOGY 2008; 109:1045-53
83. Zaugg M, Schaub MC: β3-adrenergic receptor subtype signaling in senescent heart: Nitric oxide intoxication or "endogenous" β blockade for protection? ANESTHESIOLOGY 2008; 109:956-9
84. Pietri-Rouxel F, St John Manning B, Gros J, Strosberg AD: The biochemical effect of the naturally occurring Trp64->Arg mutation on human beta3-adrenoceptor activity. Eur J Biochem 1997; 247:1174-9
85. Candelore MR, Deng L, Tota LM, Kelly LJ, Cascieri MA, Strader CD: Pharmacological characterization of a recently described human beta 3-adrenergic receptor mutant. Endocrinology 1996; 137:2638-41
86. Pacanowski MA, Zineh I, Li H, Johnson BD, Cooper-DeHoff RM, Bittner V, McNamara DM, Sharaf BL, Merz CN, Pepine CJ, Johnson JA: Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women's Ischemia Syndrome Evaluation. J Transl Med 2008; 6:11
87. Wang Y, Luk AO, Ma RC, So WY, Tam CH, Ng MC, Yang X, Baum L, Lam V, Tong PC, Chan JC: Independent predictive roles of eotaxin Ala23Thr, paraoxonase 2 Ser311Cys and beta-adrenergic receptor Trp64Arg polymorphisms on cardiac disease in type 2 diabetes-an 8-year prospective cohort analysis of 1297 patients. Diabet Med 2010; 27:376-83
88. Amour J, Loyer X, Le Guen M, Mabrouk N, David J-S, Camors E, Carusio N, Vivien B, Andriantsitohaina R, Heymes C, Riou B: Altered contractile response due to increased β3-adrenoceptor stimulation in diabetic cardiomyopathy: The role of nitric oxide synthase 1-derived nitric oxide. ANESTHESIOLOGY 2007; 107:452-60
89. Liggett SB, Cresci S, Kelly RJ, Syed FM, Matkovich SJ, Hahn HS, Diwan A, Martini JS, Sparks L, Parekh RR, Spertus JA, Koch WJ, Kardia SLR, Dorn Ii GW: A GRK5 polymorphism that inhibits β-adrenergic receptor signaling is protective in heart failure. Nat Med 2008; 14:510-7
90. Frey UH, Adamzik M, Kottenberg-Assenmacher E, Jakob H, Manthey I, Broecker-Preuss M, Bergmann L, Heusch G, Siffert W, Peters J, Leineweber K: A novel functional haplotype in the human GNAS gene alters Gαs expression, responsiveness to β-adrenoceptor stimulation, and peri-operative cardiac performance. Eur Heart J 2009; 30:1402-10
91. Gardiner SJ, Begg EJ: Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006; 58: 521-90
92. Owen RP, Sangkuhl K, Klein TE, Altman RB: Cytochrome P450 2D6. Pharmacogenet Genomics 2009; 19:559-62
93. Zanger U, Raimundo S, Eichelbaum M: Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004; 369:23-37
94. Daly AK, Brockmoller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang JD, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Steen VM, Wolf CR, Zanger UM: Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6:193-201
95. Ismail R, Teh LK: The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients. J Clin Pharm Ther 2006; 31:99-109
96. Nozawa T, Taguchi M, Tahara K, Hashimoto Y, Igarashi N, Nonomura M, Kato B-I, Igawa A, Inoue H: Influence of CYP2D6 genotype on metoprolol plasma concentration and β-adrenergic inhibition during long-term treatment: A comparison with bisoprolol. J Cardiovasc Pharmacol 2005; 46:713-20
97. Rau Ta, Heide Ra, Bergmann Kb, Wuttke Ha, Werner Ua, Feifel Na, Eschenhagen Ta: Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 2002; 12:465-72
98. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C: Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116:496-526
99. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006; 368:704
100. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE: The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992; 34:262-5
101. Transon C, Leemann T, Dayer P: In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996; 50:209-15
102. Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, Spertus JA: β2-adrenergic receptor genotype and survival among patients receiving β-blocker therapy after an acute coronary syndrome. JAMA 2005; 294:1526-33
103. Badgett RG, Lawrence VA, Cohn SL: Variations in pharmacology of β-blockers may contribute to heterogeneous results in trials of perioperative β-blockade. ANESTHESIOLOGY 2010; 113:585-92
104. Wallace AW, Au S, Cason BA: Perioperative β-blockade: Atenolol is associated with reduced mortality when compared to metoprolol. ANESTHESIOLOGY 2011; 114:824-36
105. Nagele P, Rao LK, Penta M, Kallogjeri D, Spitznagel EL, Cavallone LF, Nussenbaum B, Piccirillo JF: Postoperative myocardial injury after major head and neck cancer surgery. Head Neck 2011; 33:1085-91